[1] R. W. Thompson, P. J. Geraghty, and J. K. Lee, “Abdominal aortic aneurysms: basic mechanisms and clinical implications,” Current Problems in Surgery, vol. 39, no. 2, pp. 110–230, 2002.
[2] J. A. Curci and R. W. Thompson, “Adaptive cellular immunity in aortic aneurysms: cause, consequence, or context?” The Journal of Clinical Investigation, vol. 114, no. 2, pp. 168–171, 2004.
[3] P. J. Murray and T. A. Wynn, “Protective and pathogenic functions of macrophage sebsets,” Nature Reviews Immunology, vol. 11, pp. 723–737, 2011.
[4] M. A. Dale, W. Xiong, J. S. Carson et al., “Elastin-derived peptides promote abdominal aortic aneurysm formation by modulating M1/M2 macrophage polarization,” The Journal of Immunology, vol. 196, no. 11, pp. 4536–4543, 2016.
[5] A. Busch, C. Grimm, E. Hartmann et al., “Vessel wall morphol- ogy is equivalent for different artery types and localizations of advanced human aneurysms,” Histochemistry and Cell Biology, vol. 148, no. 4, pp. 425–433, 2017.
[6] B. Samuelsson, “Leukotrienes: mediators of immediate hyper- sensitivity reactions and inflammation,” Science, vol. 220, no. 4597, pp. 568–575, 1983.
[7] B. Dahlen and S.-E. Dahlen, “Leukotrienes as mediators of airway obstruction and inflammation in asthma,” Clinical & Experimental Allergy Reviews, vol. 25, no. 2, pp. 50–54, 1995.
[8] L. Zhao, M. P. W. Moos, R. Gra¨bner et al., “The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm,” Nature Medicine, vol. 10, no. 9, pp. 966–973, 2004.
[9] C. D. Funk, “Leukotriene modifiers as potential therapeutics for cardiovascular disease,” Nature Reviews Drug Discovery, vol. 4, no. 8, pp. 664–672, 2005.
[10] E. Ingelsson, L. Yin, and M. Ba¨ck, “Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease,” The Journal of Allergy and Clinical Immunology, vol. 129, no. 3, pp. 702–707, 2012.
[11] A. Di Gennaro, A. C. Arau´jo, A. Busch et al., “Cys- teinyl leukotriene receptor 1 antagonism prevents experimen- tal abdominal aortic aneurysm,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 115, no. 8, pp. 1907–1912, 2018.
[12] A. Yamawaki-Ogata, R. Hashizume, M. Satake et al., “A doxy- cycline loaded, controlled-release, biodegradable fiber for the treatment of aortic aneurysms,” Biomaterials, vol. 31, no. 36, pp. 9554–9564, 2010.
[13] X. Di, X. Tang, and X. Di, “Montelukast inhibits oxidized low- density lipoproteins (ox-LDL) induced vascular endothelial attachment: An implication for the treatment of atherosclero- sis,” Biochemical and Biophysical Research Communications, vol. 486, no. 1, pp. 58–62, 2017.
[14] A. Yamawaki-Ogata, X. Fu, R. Hashizume et al., “Therapeutic potential of bone marrow-derived mesenchymal stem cells in formed aortic aneurysms of a mouse model,” European Journal of Cardio-Thoracic Surgery, vol. 45, no. 5, pp. e156–e165, 2014.
[15] R. Hashizume, A. Yamawaki-Ogata, Y. Ueda, W. R. Wagner, and Y. Narita, “Mesenchymal stem cells attenuate angiotensin II- induced aortic aneurysm growth in apolipoprotein E-deficient mice,” Journal of Vascular Surgery, vol. 54, no. 6, pp. 1743–1752, 2011.
[16] T. R. Jones, M. Labelle, M. Belley et al., “Pharmacology of mon- telukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist,” Canadian Journal of Physiology and Pharmacology, vol. 73, no. 2, pp. 191–201, 1995.
[17] J. Suzuki and M. Nishikibe, “Pharmacological profile and clin- ical effects of montelukast sodium (Singulair chewable tablet), an antiasthmatic agent,” Folia Pharmacologica Japonica, vol. 120, no. 5, pp. 343–352, 2002.
[18] S.-Y. Eum, K. Maghni, Q. Hamid, H. Campbell, D. H. Eidelman, and J. G. Martin, “Involvement of the cysteinyl-leukotrienes in allergen-induced airway eosinophilia and hyperresponsiveness in the mouse,” American Journal of Respiratory Cell and Molec- ular Biology, vol. 28, no. 1, pp. 25–32, 2003.
[19] K. W. Johnston, R. B. Rutherford, M. D. Tilson, D. M. Shah, L. Hollier, and J. C. Stanley, “Suggested standards for reporting on arterial aneurysms. subcommittee on reporting standards for arterial aneurysms, ad hoc committee on reporting standards, society for vascular surgery and north american chapter, inter- national society for cardiovascular surgery,” Journal of Vascular Surgery, vol. 13, no. 3, pp. 452–458, 1991.
[20] J. A. Jones, C. Beck, J. R. Barbour et al., “Alterations in aortic cellular constituents during thoracic aortic aneurysm development: Myofibroblast-mediated vascular remodeling,” The American Journal of Pathology, vol. 175, no. 4, pp. 1746–1756, 2009.
[21] Y. Koyama and K. Tanaka, “Intracerebroventricular administra- tion of an endothelin ET𝐵-receptor agonist increases expression of matrix metalloproteinase-2 and -9 in rat brain,” Journal of Pharmacological Sciences, vol. 114, no. 4, pp. 433–443, 2010.
[22] H. Qiu, A. Gabrielsen, H. E. Agardh et al., “Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 103, no. 21, pp. 8161–8166, 2006.
[23] M. Mehrabian, H. Allayee, J. Wong et al., “Identification of 5- Lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice,” Circulation Research, vol. 91, no. 2, pp. 120–126, 2002.
[24] A. Di Gennaro, D. Wagsater, M. I. Mayranpaa et al., “Increased expression of leukotriene C4 synthase and predominant for- mation of cysteinyl-leukotrienes in human abdominal aortic aneurysm,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 107, no. 49, pp. 21093–21097, 2010.
[25] M. Er¸sahin, O¨ . C¸ evik, D. Akakin et al., “Montelukast inhibits caspase-3 activity and ameliorates oxidative damage in the spinal cord and urinary bladder of rats with spinal cord injury,” Prostaglandins & Other Lipid Mediators, vol. 99, no. 3-4, pp. 131– 139, 2012.
[26] J. Jawien, M. Gajda, P. Wołkow, J. Zuran´ska, R. Olszanecki, and R. Korbut, “The effect of montelukast on atherogenesis in apoE/LDLR - Double knockout mice,” Journal of Physiology and Pharmacology, vol. 59, no. 3, pp. 633–639, 2008.
[27] D. Liu, S. Ge, G. Zhou et al., “Montelukast inhibits Matrix metalloproteinases expression in atherosclerotic rabbits,” Car- diovascular Drugs and Therapy, vol. 23, no. 6, pp. 431–437, 2009.
[28] S. Ge, G. Zhou, S. Cheng et al., “Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model,” Atherosclerosis, vol. 205, no. 1, pp. 74–79, 2009.
[29] W. F. Johnston, M. Salmon, N. H. Pope et al., “Inhibition of interleukin-1𝛽 decreases aneurysm formation and progression in a novel model of thoracic aortic aneurysms,” Circulation, vol. 130, supplement 1, no. 11, pp. S51–S59, 2014.
[30] A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati, “The chemokine system in diverse forms of macrophage activation and polarization,” Trends in Immunology, vol. 25, no. 12, pp. 677–686, 2004.
[31] R. L. Lopes, T. J. Borges, R. F. Zanin, and C. Bonorino, “IL-10 is required for polarization of macrophages to M2-like phenotype by mycobacterial DnaK (heat shock protein 70),” Cytokine, vol. 85, pp. 123–129, 2016.
[32] I. Stelmach, J. Jerzynska, and P. Kuna, “A randomized, double- blind trial of the effect of glucocorticoid, antileukotriene and 𝛽-agonist treatment on IL-10 serum levels in children with asthma,” Clinical & Experimental Allergy, vol. 32, no. 2, pp. 264– 269, 2002.
[33] I. Stelmach, P. Majak, J. Jerzynska, and P. Kuna, “The effect of treatment with montelukast on in vitro interleukin-10 produc- tion of mononuclear cells of children with asthma,” Clinical & Experimental Allergy, vol. 35, no. 2, pp. 213–220, 2005.
[34] E. L. Henderson, Y.-J. Geng, G. K. Sukhova, A. D. Whittemore, J. Knox, and P. Libby, “Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms,” Circulation, vol. 99, no. 1, pp. 96–104, 1999.
[35] R. A. Garc´ıa, D. P. Pantazatos, C. R. Gessner, K. V. Go, V. L. Woods Jr., and F. J. Villarreal, “Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycy- cline investigated by deuterium exchange mass spectrometry,” Molecular Pharmacology, vol. 67, no. 4, pp. 1128–1136, 2005.